Assessing the capacity of available pharmaceuticals to protect human PSC-derived cardiomyocytes from anthracycline cardiotoxicity

Authors:

Abstract
No abstract available
Funding Information
  • Medical Research Future Fund (MRF2024440)
  • Medical Research Future Fund (MRF2024440)
  • Medical Research Future Fund (MRF2024440)
  • Medical Research Future Fund (MRF2024440)
  • Kids' Cancer Project
  • Children’s Cancer Foundation
  • Royal Children’s Hospital Foundation
  • National Health and Medical Research Council of Australia (GNT2008376)
  • Stafford Fox Medical Research Foundation
  • The Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW (NNF21CC0073729)
  • The Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW (NNF21CC0073729)
  • National Heart Foundation of Australia (GNT105525)